Elite Pharmaceuticals Inc (OTC: ELTP) Stock Gains After Commercial Launch of Generic Vyvanse(R)

There are some companies that are expected to come onto the radars of investors this morning in a big way, and one of those is Elite Pharmaceuticals Inc. (OTCQB: ELTP). On Thursday, the company had seen its stock come into focus among investors following an announcement and clocking gains of 4% as a consequence. 

New Product Launch

The launch of a new product almost always leads to significant enthusiasm among investors, and that is what happened with the Elite Pharmaceuticals stock on Thursday. The company announced that it launched the generic version of the Vyvanse product in varied strengths of 70 mg, 60 mg, 50 mg, 40 mg, 30 mg, 20 mg, and 10 mg capsules. It is going to be interesting to see if the Elite Pharmaceuticals stock can maintain its momentum and end the week with further gains or not.

Key Details

The product in question is meant to treat ADHD (attention deficit hyperactivity disorder) and would be marketed and sold under the company’s Elite Pharmaceuticals Inc. label. As per data from IQVIA, the yearly sales for the product in the past 12 months ending in October 2024 came in at $4.3 billion. It may be a good time to add the stock to your watchlists.

Fundamentals

P/E Ratio	-93.1500
PEG Ratio	-0.08
Price to Book	12.42
Price to Cash Flow	97.1727
Price to Free Cash Flow	160.35
Total Sales (TTM)	71.17 M
Revenue per Share (TTM)	0.07
Shares Outstanding	1.068 B
Share Float (%)	833.24 M (78.00%)
% Held by Institutions	0.01